M4 Allosteric Modulator Compounds for Selective CNS Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia, are limited by the lack of highly selective activators for the M4 subtype, leading to adverse effects due to activation of peripheral receptors, and previous attempts to develop such activators have been unsuccessful due to the high conservation of the orthosteric ACh binding site.
Innovation Solution
Development of compounds that act at allosteric sites on muscarinic acetylcholine receptors (mAChRs), specifically targeting the M4 subtype, which are less conserved and can augment receptor activity through allosteric potentiation and agonism, avoiding the limitations of the orthosteric site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then therapeutic efficacy is improved, but gastrointestinal side effects and hepatotoxicity increase
Solution Approach 1:
The invention segments the cholinergic system into specific receptor subtypes (M1, M3, M5 for cognitive functions) versus peripheral receptors (M2, M3 for autonomic functions). By designing selective M1/M3/M5 agonists that do not activate peripheral M2 receptors, the treatment achieves central therapeutic efficacy while avoiding peripheral gastrointestinal side effects and hepatotoxicity associated with non-selective AChE inhibitors
Solution Approach 2:
The invention applies local quality by creating compounds with subtype-specific selectivity for central muscarinic receptors. The agonists are designed to selectively bind to and activate M1, M3, and/or M5 receptor subtypes in the brain while having minimal affinity for peripheral M2 receptors, thereby providing localized therapeutic action in the central nervous system without affecting peripheral cholinergic functions
2Reliability
If selective M4 agonists are developed, then cognitive function improvement is enhanced, but selectivity is reduced due to high conservation of orthosteric binding site
Solution Approach 1:
The invention transitions from the traditional orthosteric binding site (one-dimensional competition at the acetylcholine binding pocket) to allosteric modulation (adding a new dimension of receptor interaction). Allosteric modulators bind to distinct sites on the receptor that are not highly conserved across subtypes, allowing for selective modulation of M4 receptor function while avoiding cross-reactivity with other muscarinic subtypes
Solution Approach 2:
The invention uses allosteric modulators as intermediaries that indirectly influence receptor activation. Rather than directly competing for the orthosteric binding site, these compounds bind to allosteric sites and modulate receptor activity through conformational changes, providing a mechanism for selective M4 agonism that overcomes the limitation of orthosteric site conservation
3Reliability
If mAChR agonists are administered to activate muscarinic receptors, then cholinergic function is augmented, but peripheral receptor activation causes adverse effects
Solution Approach 1:
The invention segments muscarinic receptor activation into central versus peripheral compartments. By designing agonists with high selectivity for central M1, M3, and/or M5 receptor subtypes and minimal activity at peripheral M2 receptors, the treatment augments central cholinergic function for cognitive improvement while avoiding peripheral adverse effects such as bradycardia, GI distress, and excessive salivation
Solution Approach 2:
The invention applies local quality by creating compounds with spatially selective receptor subtype profiles. The agonists are engineered to preferentially activate specific central muscarinic receptor subtypes (M1, M3, M5) while having negligible affinity for peripheral M2 receptors, thereby concentrating therapeutic effects in the central nervous system and minimizing peripheral adverse effects
Data Source
AI summary
Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.